FORVM GEOPOLITICA
Independent Commentary on a Fractured World



China's Breakthroughs Are Ending Diseases—And Threatening Big Pharma's Business Model

In a scientific breakthrough with the potential to transform global healthcare, Chinese researchers have unveiled a stem cell therapy capable of reversing both Type 1 and Type 2 diabetes.

Felix Abt

Wed 01 Oct 2025

This innovation could offer hope to over 500 million people worldwide living with the chronic disease—and it poses a serious challenge to the multi-billion-dollar pharmaceutical industry built on managing, not curing, diabetes.[1]

And this is only the beginning.

While the West has waged a slow, incremental "war on cancer," China is rewriting the playbook. For decades, Western pharmaceutical giants have profited from treatments that extend life by months rather than years. Now, a wave of radical medical innovations emerging from Chinese labs signals a potential paradigm shift in how we treat—and even cure—cancer. The impact is profound not only in terms of saving lives but also in shielding patients from financial devastation: traditional chemotherapy costs $10,000–$200,000 per year, depending on the drugs and regimen, making cancer a leading driver of high medical bills in the U.S. and a major source of Big Pharma profits.[2]

Unlike their Western counterparts, Chinese labs are **pursuing cures, not just treatments**, targeting chronic diseases at their root rather than managing symptoms. Simultaneously, Chinese companies are **reinventing patient care** with affordable, user-friendly innovations—from glucose monitors to insulin pumps—while improving access, distribution, and support. This combination of cutting-edge science and systemic healthcare innovation positions China to **reshape the global medical landscape**, offering both life-saving breakthroughs and a more accessible, patient-centered approach to care.[3]

The “Tumor-to-Pork” Revolution

In what sounds like science fiction, Chinese scientists have engineered a virus that tricks the immune system into identifying cancer cells as foreign pig tissue. The result? A **hyperacute immune response** that doesn’t just suppress tumors—it obliterates them.[4]

One woman with advanced cervical cancer was declared cured. Not in remission—**cured**.

And this isn’t an anomaly. Early trials report a **90% success rate**. Yet Western media has remained conspicuously silent.[5]

CAR-T Therapy—in Just One Night

Once hailed as the future of cancer treatment, CAR-T therapy in the West takes weeks of expensive, individualized cell engineering. In China, biotech firms have compressed that process into a **single night**.[6]

The outcome? Leukemia remission rates above 90%, and the therapy is being scaled faster than regulators can respond.[7]

Gene Editing, Reimagined

Chinese researchers are pioneering **in vivo gene editing**—transforming immune cells inside the body to fight cancer, without lab-grown cells or high-cost logistics. It's fast, low-cost, and effective—threatening to upend the economics of cancer care worldwide.[8]

Gene Editing, Reimagined

Chinese researchers are pioneering **in vivo gene editing**—transforming immune cells inside the body to fight cancer, without lab-grown cells or high-cost logistics. It's fast, low-cost, and effective—threatening to upend the economics of cancer care worldwide.[8]

Why China Is Likely to Win the Medical Race:

- **Scale:** A vast domestic patient population enables rapid clinical testing.[9]
- **Speed:** State-backed innovation faces fewer bureaucratic delays.[10]
- **Cost:** Therapies are developed and deployed at a fraction of Western prices.[10]

It is not the concern for ethics, but the fear of losing hegemony that drives the debate

Critics—often closely intertwined with the Western pharmaceutical-industrial complex—regularly raise objections regarding China's transparency, ethical standards, and regulatory practices.[11] While some of these criticisms may appear superficially valid, they often conceal a more fundamental anxiety: What happens if the breakthrough in the fight against cancer does not come from Harvard or Oxford—but from a research lab in Guangzhou? And what if, as a result, the highly profitable markets of the giant Western healthcare industry begin to falter?

Boardroom greed, record payouts — China's researchers are about to crash the party.

If China cracks the code first, it won't just be a medical milestone. It will mark a **geopolitical shift**—a soft-power coup that challenges global narratives about leadership, innovation, and moral authority.[12]

Final Insights: COVID-19 as a Lens on Disinformation and Misperception

China's healthcare push isn't just scientific—it aligns with the national goal of **"common prosperity."** While the country has invested heavily in biomedical research, it has also taken a cautious, risk-averse approach, starkly illustrated during the COVID-19 pandemic.[13]

Much of this, however, was lost in translation—or filtered out entirely—by Western media. Consider the following realities, rarely acknowledged in mainstream reporting:

- No vaccine mandate was ever imposed in China, despite its "authoritarian" label.[14]
- Though Chinese labs were early pioneers of mRNA technology, the government refused to approve untested mRNA vaccines—citing safety concerns.[15]

- Despite global narratives, China never implemented a nationwide lockdown. For much of the pandemic, large parts of the country were open, with mask use optional.[16]
- Stringent lockdowns occurred only in regions with limited ICU capacity, where overwhelmed local systems necessitated containment. China has since massively expanded its hospital and ICU infrastructure.[17] [18] [19]

Jerry Grey, a friend who lives in China and is an avid cyclist, has crossed the country together with his Chinese wife like few others, covering thousands of kilometers—even during the Covid pandemic. He wrote to me:

"It's true, Covid policy was set at the central level, but implementation was left to local authorities and was far from uniform—over nearly three years. I traveled to many places and experienced a wide range of situations, but from February 1, 2020, until the end of 2022 there were hardly any lockdowns—apart from the moment when the world saw Shanghai being locked down. At the same time, there were lockdowns in Guangzhou, but I was still able to travel in and out. For example, Liwan might have been open while Yuexie was locked down; Huadu might have been open while neighboring Baiyun was closed. For two years there were practically no restrictions."

Photo: Jerry Grey

"In March, April, and May 2021, my wife and I traveled by bicycle for seven weeks from Zhongshan in Guangdong across the province and into Guangxi, visiting probably more than 50 cities—without encountering any restrictions. Proof of this can

be found in my WeChat Moments, where I posted almost every day."

These realities stand in stark contrast to the dominant Western portrayal of China as oppressive and anti-science. For a public long conditioned to that narrative, it can be startling to realize that highly authoritarian measures were carried out by Western governments—not China—while China develops therapies that can end chronic diseases like diabetes, cancer, and heart disease, saving countless lives and billions in healthcare costs that might otherwise line Big Pharma's pockets.

Footnotes

1. "Stem cell therapy reverses diabetes in China-led study" – *The Lancet Diabetes & Endocrinology*
2. "Cancer treatment costs: China vs. US" – *Health Affairs*, 2024 Comparative Study
3. "Chinese biotech innovations: patient-centered care and systemic change" – *MIT Technology Review*, 2025
4. "Chinese scientists engineer virus to trick immune system into attacking cancer cells" – *South China Morning Post*
5. "Tumor cells eliminated via hyperacute response: the porcine virus breakthrough" – *Nature Medicine*, 2025
6. "China's CAR-T therapy leap: overnight production and 90% remission rates" – *Nature Biotechnology*
7. "CAR-T therapy in China: low-cost, rapid rollout" – *BMJ Global Health*, 2024
8. "In vivo gene editing for cancer immunotherapy: China's low-cost breakthrough" – *Cell Reports Medicine*
9. "Why China leads in biotech scale: population and data advantage" – *MIT Technology Review*
0. "China's regulatory model for rapid medical innovation" – *World Economic Forum Brief*, 2024
1. "Ethical concerns in China's biomedical research" – *The Hastings Center Report*
2. "China's biotech rise and the future of soft power" – *Foreign Affairs*, July 2025
3. "China's 'common prosperity' agenda and healthcare reform" – *Xinhua Policy Brief*, 2024
4. "COVID-19 vaccine mandates by country" – *The Economist*, Global Policy Tracker
5. "Why China rejected mRNA vaccines" – *Nature News Feature*, 2023
6. "Understanding China's COVID-19 lockdowns" – *Johns Hopkins Comparative Pandemic Response Report*
7. "Localized lockdowns and hospital capacity in China" – *The BMJ*, March 2023
8. "Inside China during COVID: daily life in 2022–2023" – *Deutsche Welle YouTube Reporting Series*

9. “China’s ICU capacity expansion post-COVID” – *WHO Regional Report, East Asia*, 2024

ARTICLE TAGS: